RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab
<p>Abstract</p> <p>Background</p> <p>Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent. However, some clinical situations do not allow application of tumouricidal doses (i.e. re-irradiation) hence radiation sensitization...
Main Authors: | Weichert Wilko, Krauss Jürgen, Jensen Alexandra D, Debus Jürgen, Münter Marc W |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-11-01
|
Series: | Radiation Oncology |
Online Access: | http://www.ro-journal.com/content/5/1/102 |
Similar Items
-
Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux<sup>® </sup>and particle therapy]
by: Hinke Axel, et al.
Published: (2011-02-01) -
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
by: Freier Kolja, et al.
Published: (2011-09-01) -
Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx
by: H. Hauswald, et al.
Published: (2018-11-01) -
Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck
by: A D Jensen, et al.
Published: (2019-11-01) -
Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol
by: Simon Christian, et al.
Published: (2010-11-01)